Initial Immune Response After Exposure to or to SARS-COV-2: Similarities and Differences

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Sep 4

PMID 37662901

Authors

Alessandra Aiello

Saeid Najafi-Fard

Delia Goletti

Affiliations

Soon will be listed here.

Abstract

Tuberculosis (TB), caused by (Mtb) and Coronavirus disease-2019 (COVID-19), whose etiologic agent is severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), are currently the two deadliest infectious diseases in humans, which together have caused about more than 11 million deaths worldwide in the past 3 years. TB and COVID-19 share several aspects including the droplet- and aerosol-borne transmissibility, the lungs as primary target, some symptoms, and diagnostic tools. However, these two infectious diseases differ in other aspects as their incubation period, immune cells involved, persistence and the immunopathological response. In this review, we highlight the similarities and differences between TB and COVID-19 focusing on the innate and adaptive immune response induced after the exposure to Mtb and SARS-CoV-2 and the pathological pathways linking the two infections. Moreover, we provide a brief overview of the immune response in case of TB-COVID-19 co-infection highlighting the similarities and differences of each individual infection. A comprehensive understanding of the immune response involved in TB and COVID-19 is of utmost importance for the design of effective therapeutic strategies and vaccines for both diseases.

Citing Articles

Impact of Severity of COVID-19 in TB Disease Patients: Experience from an Italian Infectious Disease Referral Hospital.

Di Bari V, Cerva C, Libertone R, Carli S, Musso M, Goletti D Infect Dis Rep. 2025; 17(1).

PMID: 39997463 PMC: 11855733. DOI: 10.3390/idr17010011.

Management of tuberculosis risk, screening and preventive therapy in patients with chronic autoimmune arthritis undergoing biotechnological and targeted immunosuppressive agents.

Picchianti-Diamanti A, Aiello A, De Lorenzo C, Migliori G, Goletti D Front Immunol. 2025; 16:1494283.

PMID: 39963138 PMC: 11830708. DOI: 10.3389/fimmu.2025.1494283.

Trends in tuberculosis mortality among older adults in China, 2004-2021: a Joinpoint regression and age-period-cohort analysis.

Zhang M, Wang X, Xiao Y, Wang Q, Huang F, Ren X Front Public Health. 2025; 12():1500539.

PMID: 39835304 PMC: 11743160. DOI: 10.3389/fpubh.2024.1500539.

Interaction between type 2 diabetes and past COVID-19 on active tuberculosis.

Calles-Cabanillas L, Aguillon-Duran G, Ayala D, Caso J, Garza M, Joya-Ayala M BMC Infect Dis. 2024; 24(1):1383.

PMID: 39633274 PMC: 11616277. DOI: 10.1186/s12879-024-10244-z.

Immunomodulatory effects of cysteamine and its potential use as a host-directed therapy for tuberculosis.

Najafi-Fard S, Farroni C, Petrone L, Altera A, Salmi A, Vanini V Front Immunol. 2024; 15:1411827.

PMID: 39530101 PMC: 11550979. DOI: 10.3389/fimmu.2024.1411827.

References

Rajah M, Bernier A, Buchrieser J, Schwartz O . The Mechanism and Consequences of SARS-CoV-2 Spike-Mediated Fusion and Syncytia Formation. J Mol Biol. 2021; 434(6):167280. PMC: 8485708. DOI: 10.1016/j.jmb.2021.167280. View

Petrone L, Tortorella C, Aiello A, Farroni C, Ruggieri S, Castilletti C . Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple Sclerosis. Front Neurol. 2022; 13:881988. PMC: 9194677. DOI: 10.3389/fneur.2022.881988. View

Reiley W, Calayag M, Wittmer S, Huntington J, Pearl J, Fountain J . ESAT-6-specific CD4 T cell responses to aerosol Mycobacterium tuberculosis infection are initiated in the mediastinal lymph nodes. Proc Natl Acad Sci U S A. 2008; 105(31):10961-6. PMC: 2504808. DOI: 10.1073/pnas.0801496105. View

Khan N, Vidyarthi A, Amir M, Mushtaq K, Agrewala J . T-cell exhaustion in tuberculosis: pitfalls and prospects. Crit Rev Microbiol. 2016; 43(2):133-141. DOI: 10.1080/1040841X.2016.1185603. View

du Bruyn E, Stek C, Daroowala R, Said-Hartley Q, Hsiao M, Schafer G . Effects of tuberculosis and/or HIV-1 infection on COVID-19 presentation and immune response in Africa. Nat Commun. 2023; 14(1):188. PMC: 9836341. DOI: 10.1038/s41467-022-35689-1. View

Valdebenito S, Bessis S, Annane D, de la GrandMaison G, Cramer-Borde E, Prideaux B . COVID-19 Lung Pathogenesis in SARS-CoV-2 Autopsy Cases. Front Immunol. 2021; 12:735922. PMC: 8521087. DOI: 10.3389/fimmu.2021.735922. View

Nair V, Franco L, Zacharia V, Khan H, Stamm C, You W . Microfold Cells Actively Translocate Mycobacterium tuberculosis to Initiate Infection. Cell Rep. 2016; 16(5):1253-1258. PMC: 4972672. DOI: 10.1016/j.celrep.2016.06.080. View

Silva M, Ribeiro L, Gouveia M, Marcelino B, Dos Santos C, Lima K . Hyperinflammatory Response in COVID-19: A Systematic Review. Viruses. 2023; 15(2). PMC: 9962879. DOI: 10.3390/v15020553. View

Lempp F, Soriaga L, Montiel-Ruiz M, Benigni F, Noack J, Park Y . Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies. Nature. 2021; 598(7880):342-347. DOI: 10.1038/s41586-021-03925-1. View

10.

Stochino C, Villa S, Zucchi P, Parravicini P, Gori A, Raviglione M . Clinical characteristics of COVID-19 and active tuberculosis co-infection in an Italian reference hospital. Eur Respir J. 2020; 56(1). PMC: 7263070. DOI: 10.1183/13993003.01708-2020. View

11.

Cooper A . Cell-mediated immune responses in tuberculosis. Annu Rev Immunol. 2009; 27:393-422. PMC: 4298253. DOI: 10.1146/annurev.immunol.021908.132703. View

12.

Goletti D, Weissman D, Jackson R, Graham N, Vlahov D, Klein R . Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol. 1996; 157(3):1271-8. View

13.

Ashenafi S, Brighenti S . Reinventing the human tuberculosis (TB) granuloma: Learning from the cancer field. Front Immunol. 2023; 13:1059725. PMC: 9797505. DOI: 10.3389/fimmu.2022.1059725. View

14.

Mohareer K, Asalla S, Banerjee S . Cell death at the cross roads of host-pathogen interaction in Mycobacterium tuberculosis infection. Tuberculosis (Edinb). 2018; 113:99-121. DOI: 10.1016/j.tube.2018.09.007. View

15.

De Marco L, DOrso S, Pirronello M, Verdiani A, Termine A, Fabrizio C . Assessment of T-cell Reactivity to the SARS-CoV-2 Omicron Variant by Immunized Individuals. JAMA Netw Open. 2022; 5(4):e2210871. PMC: 9034402. DOI: 10.1001/jamanetworkopen.2022.10871. View

16.

Bussani R, Schneider E, Zentilin L, Collesi C, Ali H, Braga L . Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology. EBioMedicine. 2020; 61:103104. PMC: 7677597. DOI: 10.1016/j.ebiom.2020.103104. View

17.

Sette A, Crotty S . Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021; 184(4):861-880. PMC: 7803150. DOI: 10.1016/j.cell.2021.01.007. View

18.

Chauss D, Freiwald T, McGregor R, Yan B, Wang L, Nova-Lamperti E . Autocrine vitamin D signaling switches off pro-inflammatory programs of T1 cells. Nat Immunol. 2021; 23(1):62-74. PMC: 7612139. DOI: 10.1038/s41590-021-01080-3. View

19.

Suthar M, Zimmerman M, Kauffman R, Mantus G, Linderman S, Hudson W . Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients. Cell Rep Med. 2020; 1(3):100040. PMC: 7276302. DOI: 10.1016/j.xcrm.2020.100040. View

20.

Bjorkstrom N, Strunz B, Ljunggren H . Natural killer cells in antiviral immunity. Nat Rev Immunol. 2021; 22(2):112-123. PMC: 8194386. DOI: 10.1038/s41577-021-00558-3. View